Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ApTOLL in COVID-19
NCT05293236Phase 1Terminated
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aptoll in coronavirus disease 2019 (COVID-19) (4 arms). Primary endpoints: Incidence of Death at 28 days, Incidence of Adverse Events at 28 days and 2 more. Started Jan 2022; status: terminated.
02
Drugs
aptoll
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05293236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293236.